Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus
- PMID: 1465459
- PMCID: PMC50727
- DOI: 10.1073/pnas.89.24.12202
Approach to a retrovirus vaccine: immunization of mice against Friend virus disease with a replication-defective Friend murine leukemia virus
Abstract
In an initial attempt to test the ability of replication-defective retroviruses to immunize against immunologically related pathogenic viruses, we have worked with the erythroleukemogenic Friend retrovirus complex (FV), which consists of a replication-competent helper component, Friend murine leukemia virus (FMuLV), and a related defective pathogenic component, spleen focus-forming virus (SFFV). An 81-base-pair deletion was introduced into the p15E-encoding region of the env gene of an otherwise replication-competent molecular clone of the FMuLV provirus. After transfection of this clone into cells that package the viral RNA in MuLV coats, infectious virus was released into the culture medium. Mouse fibroblasts infected with this virus, here called delta FMuLV, expressed the truncated viral env gene products in their cytoplasm but not on cell surfaces, and culture fluids from these cells did not transmit the infection to fresh mouse fibroblasts. In preliminary experiments, immunization of mice of H-2-congenic BALB/c strains with delta FMuLV conferred levels of immunity to FV disease ranging from weak to relatively strong. Immunized mice developed anti-FV IgM and IgG antibodies and cytotoxic T cells. Mice observed for 15 weeks after the first of two immunizations showed no detectable pathology, but delta FMuLV DNA was detectable in livers of some immunized mice for at least 3-6 weeks. These results suggest that our approach to development of retrovirus vaccines may be a useful one.
Similar articles
-
Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities.J Exp Med. 1986 Jul 1;164(1):211-26. doi: 10.1084/jem.164.1.211. J Exp Med. 1986. PMID: 2425028 Free PMC article.
-
Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.PLoS Pathog. 2019 Sep 30;15(9):e1008043. doi: 10.1371/journal.ppat.1008043. eCollection 2019 Sep. PLoS Pathog. 2019. PMID: 31568492 Free PMC article.
-
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.Science. 1986 Nov 7;234(4777):728-31. doi: 10.1126/science.3490689. Science. 1986. PMID: 3490689
-
Host genetic factors that control immune responses to retrovirus infections.Vaccine. 2008 Jun 6;26(24):2981-96. doi: 10.1016/j.vaccine.2008.01.004. Epub 2008 Jan 22. Vaccine. 2008. PMID: 18255203 Review.
-
Immune control and prevention of chronic Friend retrovirus infection.Front Biosci. 2007 Jan 1;12:1544-51. doi: 10.2741/2167. Front Biosci. 2007. PMID: 17127401 Review.
Cited by
-
Immunity to retroviral infection: the Friend virus model.Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7811-6. doi: 10.1073/pnas.94.15.7811. Proc Natl Acad Sci U S A. 1997. PMID: 9223268 Free PMC article. Review.
-
Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.J Virol. 2010 Feb;84(4):1967-76. doi: 10.1128/JVI.01840-09. Epub 2009 Dec 9. J Virol. 2010. PMID: 20007267 Free PMC article.
-
Koala retroviruses: characterization and impact on the life of koalas.Retrovirology. 2013 Oct 23;10:108. doi: 10.1186/1742-4690-10-108. Retrovirology. 2013. PMID: 24148555 Free PMC article. Review.
-
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection.Retrovirology. 2016 Apr 14;13:24. doi: 10.1186/s12977-016-0258-9. Retrovirology. 2016. PMID: 27076190 Free PMC article. Review.
-
Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.J Virol. 1998 Aug;72(8):6554-8. doi: 10.1128/JVI.72.8.6554-6558.1998. J Virol. 1998. PMID: 9658099 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources